Boehringer Ingelheim launches new product Willine

Yangzhou, October 28, 2021/PRNewswire/ - Boehringer Ingelheim, a global leader in the field of animal health, announced the official listing of the first domestic vaccine to prevent Marek's disease and infectious disease in chickens with a long feeding cycle Weililing® is a vaccine product for two immunosuppressive diseases of bursal disease
.

This product can help improve the health of chickens, and contribute to ensuring the stable supply of safe, high-quality poultry products and improving human health

Willing

One shot to prevent two kinds of high incidence of immunosuppressive diseases in poultry and see the strength of Boehringer Ingelheim

Marek’s disease and infectious bursal disease are two types of immunosuppressive diseases that are highly prevalent in chickens, which seriously affect the health of chickens and have troubled the poultry industry for a long time
.

For this reason, Boehringer Ingelheim has successfully marketed Rispens and Vaxxitek® in the past.

Weililing® innovatively combines the advantages of Vaxxitek® and Rispens and achieves a joint enhancement effect
.

In the prevention of Marek's disease, Velalink® can produce a higher protective effect than Rispens

The successful listing of Willlink® will also be another milestone for Boehringer Ingelheim to "root China and serve China"
.

The product was developed by the Chinese team to meet the needs of Chinese hatchery customers, and is produced by the Nanchang plant, one of the Boehringer Ingelheim poultry vaccine production bases, to ensure a stable supply in the Chinese market

Committed to bringing leading integrated health management solutions to the growing Chinese poultry industry, escorting the health of chickens

Through several years of development, Boehringer Ingelheim has grown into one of the leaders in China's poultry industry
.

The company has launched many innovative products including Rispens and AVINEW+H120, and has also brought integrated health management solutions including poultry immune-related technologies and services, professional veterinary services, etc.

The poultry industry in China is developing rapidly, and the scale of production and the degree of intensification will be further improved
.

The data shows that in 2020, the country's total poultry production was 15.

Actively implement the concept of "same health" to improve the health of animals and humans

Human health, animal health and environmental health are closely intertwined.
In order to realize the common health of the three, the World Health Organization, the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health put forward the concept of "One Health"
.

As a firm practitioner of the concept of "One Health", Boehringer Ingelheim looks forward to practicing the concept of "One Health" by providing industry-leading products and integrated health management solutions to the Chinese poultry industry

Dai Huawei, head of Boehringer Ingelheim’s animal health business in Greater China, said: “We know that when animals are healthy, humans will be healthier
.

The company is committed to improving the well-being of animals and humans, and looks forward to introducing the frontiers to China’s animal health industry.

references:

1 Laboratory data of China Agricultural University

2 Economic Daily News China Economic Trend Research Institute, China Agricultural University National Agricultural and Rural Development Research Institute

About Boehringer Ingelheim's animal health business

In the field of animal health, Boehringer Ingelheim’s 9,700 animal health employees around the world are committed to show value through innovation to improve the well-being of animals and humans
.
We always respect animals, humans and the environment, and protect animals from diseases and diseases by developing solutions and providing services
.
We help customers care for the health of their animals and protect our community from life-threatening and social-threatening diseases
.
Boehringer Ingelheim is the world's second-ranked animal health company, with net sales of 4.
1 billion euros in 2020 and business covering more than 150 markets
.
Boehringer Ingelheim's diversified animal protection product portfolio in the Chinese market covers the fields of vaccines and medicines for livestock, poultry and companion animals
.
The company is currently the market leader in China's live pigs, companion animals and poultry products
.
The company has a wide-ranging presence in China, covering the complete value chain from R&D, production, sales, technical services to diagnosis and monitoring
.
Boehringer Ingelheim Animal Health is based on "rooted in China, serving China", committed to providing customers with better innovative solutions and better services, and jointly promoting industry progress and further improving the health of humans and animals
.

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world's leading biopharmaceutical companies
.
Since its establishment in 1885, Boehringer Ingelheim has always been an independent family business, and this will not change in the long run
.
The company is headquartered in Ingelheim, Germany, and has approximately 52,000 employees worldwide
.
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of humans and animals
.

Boehringer Ingelheim China is headquartered in Shanghai, and currently has more than 4,500 employees nationwide.
Its core business includes: human medicine, animal health and biopharmaceutical contract production
.
In recent years, Boehringer Ingelheim has achieved sustained growth in China, and its development speed has exceeded the average growth level of the market.
It has been awarded the "China Outstanding Employer" certification for eight consecutive years
.
China is one of Boehringer Ingelheim’s most important strategic markets.
The company incorporates the needs of Chinese patients into its global R&D strategy, and is committed to bringing more and better innovative products to Chinese patients earlier, thereby improving people’s health and life Quality
.
For more details, please visit: Boehringer Ingelheim Nanchang Plant

Founded in 1990, Nanchang Boehringer Ingelheim Animal Health Co.
, Ltd.
is Boehringer Ingelheim's poultry vaccine production plant in China
.
By the end of 2020, the plant will have a total investment of 70 million euros and an annual production capacity of 20 billion feathers, which can meet the growing demand for poultry vaccines in China and supply to other Asian countries
.

Boehringer Ingelheim's Nanchang plant mainly produces vaccines against various diseases infected with broilers and laying hens, targeting diseases such as Marek's disease, Newcastle disease, infectious bronchitis, and infectious bursal disease
.
The most outstanding achievements of the factory are the official production and launch of the Marek’s disease liquid nitrogen vaccine (Lengkeling) in China in 2002, the Newcastle Disease and Infectious Bronchitis Combination Vaccine (Vichiling) in 2006, and the chicken infectious disease in 2011.
Bursal disease and Marek’s disease carrier vaccine (Victor)
.

Source: Boehringer Ingelheim